Dr. Claudia Chudak   Marketing and Sales Application Specialist   Phone: +49 331-58184785 E-mail

 

GILUPI is a specialized medical technology company focused on the development and production of the GILUPI CellCollector™ technology, a medical device used in the upstream value chain of molecular diagnostics.

GILUPI has developed a unique and proprietary technology platform that represents a major improvement in the harvesting of rare cells, such as circulating tumour cells (“CTCs”) or circulating endothelial cells (“CECs”), directly in the patient’s blood stream. Current state of the art diagnostic analyses are based on limited volumes of blood samples and subsequent in vitro enumeration and characterization. In contrast to these methodologies, the GILUPI technology isolates the cells in vivo with high sensitivity and selectivity providing compelling and improved diagnostic value.

Application of the GILUPI technology renders living cells that today can only be harvested in sufficient numbers via biopsies. But biopsies are invasive and thus are associated with risk for the patient and are often even not available due to a lack of localized appropriate tissue (e.g. after surgery of the primary tumour or in general due to the disease e.g. in cardiovascular diseases). The advanced technology will open up previously unavailable opportunities in personalized medicine, early diagnosis as well as treatment and clinical monitoring.